Radiology and Oncology, cilt.54, sa.4, ss.480-487, 2020 (SCI-Expanded)
Background. Stereotactic ablative radiotherapy (SABR) is effective for thoracic cancer and metastases; however, adverse effects are greater for central tumors. We evaluated factors affecting outcomes and toxicities after SABR for patients with primary lung and oligometastatic tumors.